UHRF1 and cancer: UHRF1 has been credentialed as a target for cancer therapeutics [18, 20]; development of inhibitors of UHRF1 binding to hemimethylated DNA could yield a novel class of DNA demethylating agents that can relieve the DNA hypermethylation mediated epigenetic repression of tumor suppressor genes in cancer cells while potentially avoiding the pitfalls and toxicities of existing nucleoside analog DNMT inhibitor DNA demethylating agents [20, 26].